Expand NVOX Menu
NVOX MENU

NVOX ETF Profile


Family: Defiance ETFs
Name: Defiance Daily Target 2X Long NVO ETF
Inception Date: 2-Dec-2024
Termination Date:
Investment Objective: The Defiance Daily Target 2X Long NVO ETF (the "Fund") seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of NOVO Nordisk A/S - ADR (NYSE: NVO) (the "Underlying Security" or "NVO"). NVOX does not invest directly in NOVO. NOVO Nordisk A/S ("Novo Nordisk") is a Danish global pharmaceutical company. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically to provide diabetes care and other chronic conditions like obesity, hemophilia, and growth disorders. It is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The Fund will seek to achieve its objective with respect to Novo Nordisk's American Depositary Receipt (NYSE: NVO).
Prospectus
Top 10 Holdings
NOVO-NORDISK A S ADR SWAP - L - MAR 130.2800%
Cash & Other -100.2300%
NOVO-NORDISK A/S-SPONS ADR NOMURA 63.8800%
Novo Nordisk A/S NVO 6.0700%
Top 10 Holdings Weight: 100.0%
Number of Holdings: 4
Shares Outstanding: 200,000
Total Net Assets: 2,428,740
NAV: 12.14
Net Expense Ratio: 1.29%
Asset Class: Equities (Stocks)
Developed or Emerging: Developed Market Funds
Country: Denmark
Region:
Strategy:
Currency:
Commodity:
Sector: Healthcare
Industry: Pharmaceuticals
Dividend Type:
Tax Exempt State:
Maturity Duration:
Market Cap: Large Cap
Credit Quality:
Mortgage Bond Types:
Bond Type:
Gov't Bond Types:
Reit Type:
Leverage Direction/Factor: Leveraged (2x)
Is Currency Hedged: No
US or Ex-US: International